Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Mutation database helps personalized treatment of lung cancer

A groundbreaking free tool to help oncologists choose the best therapies for patients with non-small-cell lung cancer has been launched this week by scientists at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland.

26 Apr 2008

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

NovoCure presents results from breast cancer pilot study

NovoCure announced today that it presented the results from a single-arm pilot trial evaluating the Novo-TTF, a non-invasive portable medical device, combined with neo-adjuvant chemotherapy for the treatment of patients with locally advanced breast cancer.

15 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Genetic variations raise lung cancer risk for smokers and ex-smokers

Two common inherited genetic variations are associated with increased risk of lung cancer for smokers and former smokers, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 2 in the online edition of Nature Genetics.

3 Apr 2008

Long-term follow-up after percutaneous pulmonary radiofrequency ablation

Radiofrequency ablation (RFA) - an interventional treatment that "cooks" and kills lung cancer tumors with heat - greatly improves survival time from primary or metastatic inoperable lung tumors, according to a study released at the Society of Interventional Radiology's 33rd Annual Scientific Meeting.

18 Mar 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

DNA detectives find genetic markers for lung cancers most likely to recur

Researchers at the Johns Hopkins Kimmel Cancer Center have uncovered clearly recognizable genetic alterations in tumors and tissue removed from patients with early-stage lung cancers that look like good predictors of which of these cancers are more likely to recur.

13 Mar 2008

Glioblastoma multiforme responds to new treatment

One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer.

28 Feb 2008

Resisting lung cancer recurrence - Vaccine booster gives persistent immune response

What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years? This concept may no longer be a fantasy.

4 Feb 2008

Gold nanoparticles shine brightly in tumors

Solid gold nanoparticles have long been used to treat rheumatoid arthritis and more recently have shown promise in treating various types of cancer.

16 Jan 2008

Marital status doesn't affect lung cancer survival

Contrary to previous studies, married patients with lung cancer do not have longer survival, according to analysis of an extensive Mayo Clinic database in the December issue of "The Oncologist."

2 Jan 2008

Positron emission tomography may improve lung cancer diagnosis

Tumor imaging with positron emission tomography (PET) may improve the diagnosis and subsequent treatment of lung cancer patients, according to a review published online November 27 in the Journal of the National Cancer Institute.

27 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

GPRC5A gene found to be a tumor-suppressor for lung cancer

The GPRC5A gene, which is under-expressed in human lung cancer cells, suppresses lung tumors in mouse models and could provide a key to attacking lung cancer in humans, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 21 edition of The Journal of the National Cancer Institute.

14 Nov 2007

PET scans useful for some cancer treatment, but how do patients fare?

Positron emission tomography or PET scans can help clinicians diagnose and treat some cancers, but it is not clear yet whether the imaging technology helps people with cancer live longer and healthier lives, according to a comprehensive review by the U.K. National Health Service.

14 Nov 2007

Tumor-suppressor gene for lung cancer identified

14 Nov 2007

Synthetic compound promotes death of lung-cancer cells, tumors

Human lung-cancer tumors grown in mice have been shown to regress or disappear when treated with a synthetic compound that mimics the action of a naturally occurring "death-promoting" protein found in cells, researchers at UT Southwestern Medical Center report.

13 Nov 2007

FDA strengthens warnings for erythropoiesis-stimulating agents

The U.S. Food and Drug Administration has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs), which treat certain types of anemia.

13 Nov 2007

Bevacizumab improves ovarian cancer treatment

A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.

1 Nov 2007